Corcept Therapeutics’ Post

Checkout the 8th article of "Life Takes Guts" newsletter Hope On the Horizon: Exciting Research Advances in IBD Care and Treatment #IBD #CrohnsDisease #UlcerativeColitis #IBDresearch #IBDtreatment #healthcare #medicalresearch

📢 Our New NEJM Paper: G6PD Deficiency and Type 2 Diabetes We are excited to announce the publication of a groundbreaking study by Leumit Research Institute in the New England Journal of Medicine (NEJM) "Type 2 Diabetes in Patients with G6PD Deficiency". 🔍 Study Highlights: This 20-year cohort study investigated the impact of glucose-6-phosphate dehydrogenase (G6PD) deficiency on glycated hemoglobin (HbA1c) levels, diabetes management and severe diabetes outcomes for 3,913 patients with G6PD deficiency and 19,565 matched controls. The study reveals that G6PD deficiency significantly affects the reliability of HbA1c as a marker for diabetes severity. Consequently, G6PD deficient patients experienced significant delays in diabetes treatment and suffered from higher rates of diabetes complications. 📊 Key Findings: Despite similar fasting glucose levels, patients with G6PD deficiency had significantly lower HbA1c levels compared to controls (4.79% vs. 5.50%, P<0.001). Alarmingly, an HbA1c level of 6.5%—commonly used to diagnose diabetes—corresponds to much higher fasting glucose levels in G6PD deficient patients: 168 mg/dL for males and 155 mg/dL for females, compared to the standard 126 mg/dL in the general population. This disparity further increases with higher glycemic levels. 💡 Clinical Implications: These findings indicate that standard HbA1c thresholds underestimate the severity of hyperglycemia in G6PD deficient patients. This translates into delayed diabetes diagnosis and inappropriate treatment. Notably, patients with G6PD deficiency were less likely to receive disease modifying drugs such as GLP-1 agonists and SGLT2 inhibitors, which could have mitigated the damaging effect of diabetes. We further show that patients with G6PD deficiency experienced higher rates of severe diabetes complications, such as kidney disease, ischemic heart disease, and neuropathy. 🤝 Advocating for Fair Access to Medical Care: This study has very important implications for clinical practice: G6PD deficiency is prevalent in underprivileged minorities, such as people of African or Asian origin, including African Americans in the US. Ensuring that these populations receive accurate diagnoses and appropriate treatments is crucial for promoting health equity and reducing disparities in healthcare. 🏥 Call to Action: We urge healthcare providers to consider these insights when diagnosing and managing diabetes in patients with G6PD deficiency. Adjusted treatment guidelines are essential to ensure equitable and effective care for this vulnerable population. Read the full study to better understand the need to adapt diabetes management protocols for G6PD deficient individuals. 📄 https://lnkd.in/diP36Akh #Diabetes #G6PDDeficiency #Leumit #NEJM #GLP1 #SGLT2 #ClinicalPractice #HealthEquity

Interesting paper on the economic benefit of cilta-cel for patients with RRMM.

While high heart failure care costs in the U.S. are frequently reported, little is known about the specific cost contributors. A recent study led by DCRI Fellow Mark Kittipibul looks at cost differences for HF patients with ≤40% vs >40 ejection fraction, and how SGLT2i therapy could improve outcomes and reduce costs: https://lnkd.in/eikxyFXn #clinicalresearch #clinicaltrials #heartfailure #healthcarecosts

With GLP-1 medications impacting a wide range of conditions from high blood pressure to infertility, they often seem like a cure all solution. However, recent research highlights potential side effects, such as a higher risk of NAION. It’s a reminder of the importance of continuous monitoring and research to fully understand the implications of these treatments. Let's stay informed and cautious as we navigate these advancements. #GLP1 #Healthcare #MedicalResearch #PatientSafety https://lnkd.in/gsx3d5TU

IV push-dose Keppra in EDs for status epilepticus to measure the Adverse events of undiluted intravenous push administration of levetiracetam This study found that the rapid administration of undiluted IV levetiracetam in ED patients was associated with few adverse events. side note: doses upto 4500 mg how much time would it take to draw up 45 ml from the vials😁 damn https://lnkd.in/eYxDgVAZ

A US-wide clinical trial has provided doctors with new insights into the importance of managing #stroke patients’ blood sugar after treatment with clot-busting therapy https://lnkd.in/eMcmJwn3 #strokeawareness #strokeawarenessmonth

A new study introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients. https://buff.ly/4bxjNOW #Research #LifeSciences #Health #Biorealty

New from JN Learning: Clinical Practice Guideline for Transfusion Thresholds in Preterm Neonates https://lnkd.in/gYwj6cMX